Auvelity (Dextromethorphan HBr/Bupropion) Patent Expiration, LOE Window & CMS Spending

Auvelity (Dextromethorphan HBr/Bupropion) by Axsome Therapeutics: FDA Orange Book LOE 2043-11-28, 0 AB generics, $167.4M 2024 CMS Part D & Medicaid spend, and $1,061 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAxsome Therapeutics
FDA Application & PathwayN215430 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2043-11-28
Orange Book Patents (*PED Extensions)148 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$167.4M
2024 Medicare Part D Spend$77.1M
2024 Medicaid Spend$90.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,061 intro WAC)